ceritinib-resistant ALK mutants

Stable Identifier
R-HSA-9717323
Type
Pathway
Species
Homo sapiens
Compartment
cytosol, plasma membrane
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
ceritinib-resistant ALK mutants
Click the image above or here to open this pathway in the Pathway Browser
Ceritinib is a type I TKI that is effective against ALK driven cancers and is approved for treatment of NSCLC. Ceritinib is a second-generation TKI that shows activity against a number of crizotinib-resistant ALK alleles, however, resistance to ceritinib has also been documented. This pathway describes ALK mutants that are resistant to inhibition with ceritinib (reviewed in Lovly and Pao, 2012; Lin et al, 2017; Della Corte et al, 2018).
Literature References
PubMed ID Title Journal Year
29455642 Role and targeting of anaplastic lymphoma kinase in cancer

Troiani, T, Viscardi, G, Morgillo, F, Fasano, M, Martinelli, E, Ciardiello, F, Della Corte, CM, Di Liello, R

Mol. Cancer 2018
22323827 Escaping ALK inhibition: mechanisms of and strategies to overcome resistance

Lovly, CM, Pao, W

Sci Transl Med 2012
28122866 Targeting ALK: Precision Medicine Takes on Drug Resistance

Shaw, AT, Riely, GJ, Lin, JJ

Cancer Discov 2017
Participants
Events
Participates
as an event of
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Rothfels, K  (2021-03-22)
Reviewed
Inghirami, G  (2021-05-04)
Created
Rothfels, K  (2021-03-08)
Cite Us!